Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190395 | 0.77 | KDM4E (0.48) | KDM4ELMNAALDH1A1THRBGAA | |
| SCHEMBL3376067 | 0.77 | KDM4E (0.48) | KDM4ELMNAALDH1A1THRBGAA | |
| SCHEMBL21895375 | 0.76 | KDM4E (0.53) | KDM4ELMNAALDH1A1THRBGAA | |
| SCHEMBL13898605 | 0.74 | KDM4E (0.50) | KDM4ELMNAALDH1A1THRBGAA | |
| SCHEMBL9185122 | 0.74 | KDM4E (0.50) | KDM4ELMNAALDH1A1THRBGAA | |
| SCHEMBL18904607 | 0.72 | KDM4E (0.48) | KDM4ELMNAALDH1A1THRBGAA | |
| SCHEMBL4259381 | 0.72 | KDM4E (0.44) | KDM4ELMNAALDH1A1THRBGAA | |
| SCHEMBL3676238 | 0.71 | KDM4E (0.52) | KDM4ELMNAALDH1A1THRBGAA | |
| SCHEMBL24375938 | 0.70 | KDM4E (0.42) | KDM4ELMNAALDH1A1THRB | |
| SCHEMBL32688765 | 0.68 | KDM4E (0.45) | KDM4ELMNAALDH1A1THRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8704022-B2 | Process for producing high purity exo-alkenylnorbornene | PROMERUS, LLC (US) | 2014-04-22 | — | — | US | claimed |
| US-20260035328-A1 | CYCLIC DIENE-CONTAINING COMPOSITION, PRODUCTION METHOD FOR ALDEHYDE, PRODUCTION METHOD FOR ALCOHOL, AND PRODUCTION METHOD FOR CYCLIC DIENE-CONTAINING COMPOSITION | MITSUBISHI CHEMICAL CORPORATION (JP) | 2026-02-05 | — | — | US | disclosed |
| WO-2024219473-A1 | CYCLIC DIENE–CONTAINING COMPOSITION, PRODUCTION METHOD FOR ALDEHYDE, PRODUCTION METHOD FOR ALCOHOL, AND PRODUCTION METHOD FOR CYCLIC DIENE–CONTAINING COMPOSITION | 三菱ケミカル株式会社 | 2024-10-24 | — | — | WO | disclosed |
| US-8704022-B2 | Process for producing high purity exo-alkenylnorbornene | PROMERUS, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2181125-A1 | PROCESS FOR PRODUCING HIGH PURITY EXO-ALKENYLNORBORNENE | Promerus, LLC (US) | 2010-05-05 | — | — | EP | disclosed |
| US-20090054714-A1 | PROCESS FOR PRODUCING HIGH PURITY EXO-ALKENYLNORBORNENE | PROMERUS LLC (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009021096-A1 | PROCESS FOR PRODUCING HIGH PURITY EXO-ALKENYLNORBORNENE | PROMERUS, L.L.C. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035328-A1 | CYCLIC DIENE-CONTAINING COMPOSITION, PRODUCTION METHOD FOR ALDEHYDE, PRODUCTION METHOD FOR ALCOHOL, AND PRODUCTION METHOD FOR CYCLIC DIENE-CONTAINING COMPOSITION | ADH1C, ADH1A, ADH5 | KDM4E 1777/4885LMNA 1031/4885ALDH1A1 4/4885 |
| US-20090054714-A1 | PROCESS FOR PRODUCING HIGH PURITY EXO-ALKENYLNORBORNENE | EXOC3, EXOC1, EXOC4 | KDM4E 2981/4885LMNA 892/4885ALDH1A1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.